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Abstract
Neisseria meningitidis is a human pathogen responsible for life-threatening inflammatory diseases. Meningococcal penicillin-
bindingproteins(PBPs)andparticularlyPBP2areinvolvedinbacterialresistancetob-lactams.Herewedescribeanovelfunction
for PBP2 that activates human and mouse dendritic cells (DC) in a time and dose-dependent manner. PBP2 induces MHC II
(LOGEC50=4.7 mg/ml60.1), CD80 (LOGEC50=4.88 mg/ml60.15) and CD86 (LOGEC50=5.36 mg/ml60.1). This effect was
abolished when DCs were co-treated with anti-PBP2 antibodies. PBP2-treated DCs displayed enhanced immunogenic
properties in vitro and in vivo. Furthermore, proteins co-purified with PBP2 showed no effect on DC maturation. We show
throughdifferentinvivoandinvitro approachesthatthiseffectisnotduetoendotoxin contamination.Atthemechanistic level,
PBP2 induces nuclearlocalization of p65 NF-kB of 70.765.1%cells versus 1262.6%in untreated DCs and needs TLR4 expression
to mature DCs. Immunoprecipitation and blocking experiments showed that PBP2 binds TLR4. In conclusion, we describe a
novel function of meningococcal PBP2 as a pathogen associated molecular pattern (PAMP) at the host-pathogen interface that
could be recognized by the immune system as a danger signal, promoting the development of immune responses.
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Introduction
The penicillin-binding proteins (PBPs) are conserved proteins
which play a critical role in building the cell wall in several bacterial
pathogens by catalyzing the biosynthesis of peptidoglycan [1].
Indeed, inhibition of PBPs produces an imbalance in cell wall
metabolism resulting in growth arrest or lysis. b-lactam antibiotics
covalently link PBPs and therefore act as suicide inhibitors of PBPs.
Acquisition of PBPs with low affinity for the b-lactams is a mean of
antibiotic resistance, in addition to a decreased permeability of the
outer membrane,antibioticexport,or degradationby b-lactamases[2].
Neisseria meningitidis, a Gram-negative human pathogenic bacter-
ium, infects asymptomatically the nasopharynx of about 10% of
the population worldwide [3]. Occasionally, it provokes invasive
infections leading to inflammatory diseases such as septicaemia,
meningitis and arthritis. N. meningitidis contains three defined PBPs
[4,5]. PBP1 encoded by ponA, PBP2 encoded by penA and PBP3
encoded by pbp3[6]. Besides its role in peptidoglycan synthesis and
penicillin G resistance, we have shown that PBP2 from N.
meningitidis displays immunogenic properties. Indeed, sera from
patients convalescent of meningococcal disease recognized PBP2s
from different strains [7]. Moreover, vaccination with purified
recombinant PBP2 and administration of purified anti-PBP2
rabbit IgG antibodies conferred protection against experimental
meningococcemia in mice. Thus, PBP2 can be the target of a
protective adaptive immune response [7].
We speculated that PBP2 from N. meningitidis could also
constitute a pathogen-associated molecular pattern (PAMP) acting
as a pro-inflammatory molecule on dendritic cells (DCs). DCs
reside within the epithelium and represent a first line of defence
against invading N. meningitidis [4]. Here we show for the first time
that, in addition to the functions described above, PBP2 can also
trigger DC maturation in a TLR4-dependant manner and
therefore increase the immunogenic properties of DCs in vitro
and in vivo. A novel role for meningococcal PBP2 as a PAMP is
therefore described at the host-pathogen interface.
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Ethics statement
All animal experiments were performed under specific patho-
gen-free conditions in accordance with the European Union
Guidelines. All animal studies were conducted according to the
guidelines of the French Agriculture Ministry. The studies were
approved by the Veterinary Departmental Services committee, La
Chapelle-Sur-Erdre, and Paris France (No:E.44011; No 75-1554),
and all experiments were carried out in compliance with the
ethical rules of the INSERM and the Institut Pasteur.
Mice
The Ins-HA-transgenic mice [5] express HA of the influenza
virus in pancreatic islets and the TCR-HA512–520 transgenic mice
[7] express a TCR-specific for the H-2K
d-restricted (IYSTVASSL)
epitope of HA (De ´partement de Cryopre ´servation, Typage,
et Archivage Animal Orle ´ans, France). TLR2
2/2, TLR3
2/2,
TLR4
2/2 mice (C57/BL6 H-2K
b background) were elevated at
the Institut Pasteur (Paris, France). BALB/c mice were obtained
from Janvier (France).
Recombinant PBP2 production and purification
The recombinant plasmids pAA2 and pAD4 (pET28b har-
bouring penA or crgA, respectively) were described previously [6]
ponA which encodes for meningococcal PBP1 lacking the signal
peptide and the transmembrane domain (the first 30 codons) has
been amplified by PCR from the strain 8013 using the
oligonucleotides AA-16 (59-GCTGGTCTCCCATGACGTAT-
CCGAAACTGC-39) and AA-17,(59-CAGGCGGCCGCAAAC-
AGGGAATCCAACTGC-39) harbouring respectively BsaI and
NotI as adapters and then cloned into pET28b cut with NcoI and
XhoI restriction enzymes. The gene pbp2 of Helicobacter pylori (Hp)
without the signal peptide and the transmembrane domain
regions, was amplified from the strain 26695 [8], using the
oligonucleotides pbp2-BamHI-pACYCduet (59-CGCGGATCC-
GTTGGCTGAACGAAACATG-39) and pbp2-NotI-pACYC-
duet (59-AAGGAAAAAAGCGGCCGCTTAAAGATAGCCAA-
GCTCATAGAG-39). The PCR product was digested with
BamHI and NotI and inserted into pACYCduet (Novagen), which
was cut with the same endonucleases. The recombinant plasmids
were transformed into E. coli BL21(DE3) pLysS strain and His6-tag-
recombinant proteinswereoverexpressedand purifiedusing a nickel
nitrilotriacetic acid-agarose column (Qiagen, Du ¨ren-Germany), as
previously reported [6]. His6-tagged PBP2 was further purified
using an anion exchange column (Mono Q HR 10/10, GE
Healthcare). PBP2 was applied on to the column equilibrated with
buffer A (20 mM Tris- HCl, pH 8; 150 mM NaCl). PBP2 was
eluted using a linear NaCl gradient (from 0 M to 1.35 M), Protein
concentrations were determined spectrophotometrically by moni-
toringtheabsorbanceat278 nm.ThepurityofPBP2wasconfirmed
by SDS-PAGE and silver staining as previously described [9].
Endotoxin detection assay
The level of endotoxin in the purified preparations was
determined by a quantitative, chromogenic QCL-1000 Limulus
amoebocyte lysate (LAL) assay (Cambrex BioScience Walkersville,
Inc., alkersville, MD, USA) according to the manufacturer recom-
mendations. The detection limit of the assay was 0.01 EU/ml.
Cell preparation, culture, and treatments
Bone marrow cells were cultured in RPMI 1640 medium
supplemented with 10 ng/ml of supernatant from COS cells
transfected with murine GM-CSF cDNA, 10% FCS, 2 mM
L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and
50 mM 2-ME (all from Sigma- Aldrich). At day 8, non-adherent
cells were harvested and used for the different experiments. PBP2
was used at 10 mg/ml unless otherwise stated for 48 h. LPS (E. coli
0111:B4) was from Sigma-Aldrich and used at 50 ng/ml for 48 hs
unless otherwise stated. Polymixine B (PMB, Sigma- Aldrich) was
used at 10 mg/ml and incubated with LPS or PBP2 30 minutes
before incubation with cells. For blocking experiments, PBP2 or
LPS were pre-incubated with 5 mg polyclonal rabbit anti-PBP2
IgG [6] or irrelevant polyclonal antibody at 37uC for 1 h. In most
experiments, BMDCs were generated using C57/BL6 mice. In
diabetes induction experiments BMDCs were generated using
BALB/c mice. DCs from mouse spleens were purified according
to [10]. Human monocyte-derived DCs were generated as
previously described [11].
ELISA
Mouse ELISA kits (BD Pharmingen) for IL-12p70 and TNF-a
were used to quantify these cytokines in the culture supernatant of
treated DCs. Capsule polysaccharide were purified according to a
modification of the previously reported method [12]. Cetavlon
extraction (10%) was conducted at 4uC and followed by DNase
and RNase treatment. After phenol extraction, Nm X capsular
polysaccharide was recovered by ultracentrifugation, dialyzed and
lyophilized (yield between 2 mg and 5 mg). Coating of purified
PBP2 or purified capsular polysaccharide was performed in
ELISA plates using suspension at 1 mg/ml concentration of
protein or polysaccharide.
Flow cytometry
BMDCs were stained with anti-CD40, MHC class II, CD80,
CD86 and CD11c antibodies (BD Biosciences and Miltenyi
Biotech). The staining was analyzed in the CD11c+ gate. We used
a FACSCalibur flow cytometer and CellQuest software or a LSR
II flow cytometer and FACSDiva software (BD Biosciences).
MLR
C57/BL6 BMDCs were cultured at different ratios with 10
5
BALB/c lymph node cells. Proliferation was studied at day
three by analyzing DDAO-SE dilution by flow cytometry as
previously described [13]. For human MLR, monocyte-derived
DCs treated with PBP2 or not were cultured at different ratios
with 5610
4 allogeneic purified T cells. Proliferation was assessed
at day three by analyzing
3H-thymidine incorporation as described
by [14].
Diabetes induction
Six- to 8-wk-old Ins-HA mice were injected i.v. with 0.5610
6
CD8+ T cells (purity .95%) isolated from HA512–520 TCR-
transgenic mice [5] (Miltenyi Biotec). Twenty-four hours later,
mice were injected i.v. with 15,000 HA-loaded LPS-matured or
PBP2-treated DCs. Diabetes was monitored using Clinistix
urinalysis strips (Bayer). Mice were considered diabetic when the
glucose concentration was above 5.5 mmol/L.
Immunocytology
NF-kB nuclear translocation was analyzed by immunofluores-
cence and images were analyzed by confocal microscopy. An anti-
p65 (F-6) monoclonal antibody from Santa Cruz Biotechnology
(Santa Cruz, CA) was used at 5 mg/mL. The secondary antibody
was an antimouse-Alexa568 from Jackson (Suffolk, UK). Cell nuclei
were counterstained with TOPRO-3iodide (Molecular Probes,
Eugene, OR) and slides were mounted in ProLong AntiFade
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confocal microscope and the Leica TCS NT software.
Pull-down assays. Hec-1-B epithelial cells were treated with
10 mg of purified His6-tagged proteins. Cells were then lysed in
extraction buffer (25 mM Tris-HCl pH, 7.5, 1 mM EDTA, 1 mM
EGTA, 100 mM NaCl, 1% Triton X-100, 0.5% NP-40, 0.2 mM
PMSF and protease inhibitor cocktail) for 20 minutes at 4uC and
debris were removed by high speed centrifugation. Five hundred
mg of soluble proteins were mixed with 5 mg of anti-hTLR4 mAb
(clone 1G11, Sigma, France), or an irrelevant normal mouse IgGs.
Alternatively, soluble proteins were mixed with 5 mg of anti-
HisTag rabbit polyclonal antibody (Abcam, France) or an
irrelevant normal rabbit IgGs. The mixture was incubated for
1 hour at 4uC. Protein A-agarose beads were added to the
mixtures and the samples were incubated for an additional
30 minutes at 4uC. Agarose beads were washed extensively and
protein complexes were solubilised in 16 Laemmeli buffer and
submitted to SDS-PAGE and immunoblot using either anti-His
Tag polyclonal antibody (for anti-TLR4 immunoprecipitated
samples) or anti-TLR4 mAb (for anti-His-tag immunopre-
cipitated samples). Cells or purified proteins were used as controls
as indicated.
Binding and blocking assay for PBP2/human
TLR4. Hec-1-B cells were seeded in RPMI medium
supplemented with 5% FBS in 24 well plate at a density of 10
5
cells/well. Cells were then treated for 1 h at 37uC with increasing
amounts of purified His-tagged PBP2 in presence of anti-TLR4
blocking antibodies (clone HTA125 eBioscience, Hatfield, UK) or
an irrelevant normal mouse IgG (10 mg). After extensive wash with
HBSS supplemented with 1% FBS, cells were fixed for 15 min
with 3% paraformaldehyde. Bound PBP2 was detected using anti-
His-tag polyclonal antibody followed by HRPO-conjugated goat
anti-rabbit antibody. Colorimetric signal was detected using
HRPO substrate and quantified using multiskan Ascent reader
plate (Thermolab Systems) at 492 nm.
Statistical analysis
Statistical significance was assessed using the nonparametric
one-way ANOVA test with a Tukey post test. Differences were
considered significant when p,0.05.
Results
PBP2 induces human and mouse phenotypic DC
maturation
The main objective of the present study was to determine
whether PBP2 could be recognized by DCs as a danger signal and
therefore increase its immunogenic properties. We therefore
analyzed DC phenotypic maturation upon PBP2 treatment. We
observed that PBP2 induced expression of CD80, CD86, CD40
and MHC class II on mouse bone marrow-derived DC (BMDC)
(Figure 1A–C) in a dose and time-dependent manner (Figure 1B
and Figure S1). Importantly, PBP2 also increased the expression
of CD40, CD80, CD86, HLA-DR and the maturation marker
CD83 in human monocyte-derived DCs (Figure 1D). Although
endotoxin-free reagents were used during the purification process,
it was critical to control for potential endotoxin contamination in
the recombinant PBP2 preparations. PBP2 preparations were
directly evaluated for the presence of bacterial endotoxin using the
highly sensitive Limulus Amebocyte Lysate (LAL) assay (CAM-
BREX). The detection limit of the assay was 0.01 EU/ml.
Maximum detectable endotoxin was at 0.314 EU/ml in a
10 mg/ml PBP2sample.Theminimum LPSconcentrationrequired
to induce DC maturation under our experimental conditions in the
present study was 1 EU/ml, three times greater than the maximal
amount of LPS detectable in PBP2. To further address an eventual
role of LPS contamination, we performed two different approaches.
First, DCs were stimulated with PBP2 in the presence of the
endotoxin-neutralizing antibiotic polymyxin B (PMB) and DC
phenotype was assessed as described above. As expected, LPS-
induced phenotype was completely abolished with PMB. In clear
contrast, PBP2-induced mature phenotype was not affected by
PMB treatment in mouse and human DCs (Figure 1C–D).
Secondly, we observed that PBP2 degradation using trypsin
completely abolished its effect on DC phenotype (Figure 1E).
Taken together, we showed that PBP2 induces human and mouse
DC maturation and that this effect is not due to endotoxin
contamination. Most experiments were performed using affinity
chromatography purified PBP2 as stated in MATERIALS AND
METHODS. To exclude the possibility that the maturation of DC
was the result of a potential co-purified contaminating protein,
affinity chromatography issued PBP2 was further purified using
anion-exchange chromatography (Figure S2A and B). Impor-
tantly, similar results (i.e. PBP2-induced DC maturation) were
obtained using highly pure PBP2-containing fraction (F2), whereas
other minor fractions lacking PBP2 (F1 and F3) did not induce DC
maturation (Figure S2C). Furthermore, anti-PBP2 polyclonal
antibodies completely abolished the effect of PBP2 preparations
(Figure S2D). It is worth noting that altered PBP2 associated with
decreased susceptibility to penicillin G was undistinguishable to
‘‘wild type’’ PBP2 in inducing DC phenotypic maturation (not
shown). PBP2 treatment did not affect DC viability as assessed
through propidium iodide staining (not shown). These data
unambiguously showed that PBP2 induces DC maturation in vitro.
PBP2 increases the immunogenic properties of DCs in
vitro and in vivo. Having shown that PBP2 induced DC
phenotypic maturation, we then studied whether PBP2 could
trigger immunogenic properties in DCs. Before directly addressing
this issue, we studied cytokine production by PBP2-treated mouse
DCs. In fact, it has been shown that, in addition to increasing
expression of MHC class II and co-stimulatory molecules,, fully
matured, immunogenic DCs produce important amounts of pro-
inflammatory cytokines [15]. Indeed, phenotypically matured DCs
failing to produce IL 12p70 have been described to poorly trigger
immune responses [15]. We therefore quantified the levels of IL-
12p70 as well as TNF-a in the culture supernatant (CSN) of DCs
treated with PBP2 using Enzyme linked immunosorbent assay
(ELISA) (Figure 2A). PBP2 significantly induced IL-12p70 and
TNF-a production by mouse DCs as compared to untreated
control. Furthermore, LPS-induced IL-12p70 was completely
abolished by PMB, yet the treatment did not affect IL-12p70
induction by PBP2, excluding any effect of a contaminant
endotoxin (Figure 2A). Taken together, our results show that
PBP2 triggers DC maturation and that this effect is not due to
endotoxin contamination. We therefore addressed whether PBP2
could promote the immunogenic properties of DCs. To study this
issue, we first performed in vitro allogeneic mixed lymphocyte
reactions (MLR). Indeed, the allostimulatory capacity of DCs
could be analysed by comparing the proliferation of allogenic T
cells upon culture with untreated or PBP2-treated DCs. We
studied T cell proliferation by analyzing the dilution of the
fluorogenic probe DDAO-SE [10] (Figure 2B left panel). We
observed that the percentage of proliferating allogeneic T cells was
increased when stimulatory DCs have been previously treated with
PBP2 as compared to untreated cells. PBP2-treated DCs showed
similar capacity to stimulate allogeneic T cells as compared to
LPS-treated DCs (data not shown). PBP2-treated human
monocyte-derived DCs also increased its allostimulatory
PBP2 Induces DC Maturation through TLR4
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(Figure 2B right panel). PBP2 treatment of purified T cells
(not co-cultured with DCs) did not induce their proliferation (data
not shown). To investigate whether PBP2 treatment promotes
immunogenic DC properties in vivo, we used a transgenic mouse
model in which autoimmune diabetes is induced by mDCs. Ins-
HA transgenic mice adoptively transferred with naive anti-HA
CD8+ T cells developed diabetes in 6–9 days, only when
immunized with both matured and HA peptide-loaded DCs and
not when DCs were either immature or not loaded with HA
peptide (Figure 2D). Importantly, PBP2-treated DC triggered
diabetes as effectively as LPS-matured DCs. Altogether, these
results show that in vitro treatment of mouse DCs with PBP2
increases its immunostimulatory properties in vitro and in vivo.
Injection of PBP2 enhances IgG immune response
against meningococcal capsule in mice
We then explored the ability of PBP2 to work as an
immunological adjuvant for anti-meningococcal immune respons-
es. We immunized BALB/c mice subcutaneously with one dose of
Figure 1. PBP2 induces DC maturation. A. Gating strategy used in all the experiments using mouse BMDCs. Different staining were then
analyzed in the CD11c
+ fraction. B: Mouse BMDCs were left untreated or cultured in the presence of 10 mg/ml PBP2 for 24 or 48 hours (upper panel)
or with the indicated PBP2 doses for 48 hs (lower panel). CD80 and CD86 expressions were analyzed by FACS. Mean 6 SD from three independent
experiments is depicted in the graphs. *: p,0.05; **: p,0.01. C: PBP-2-induced phenotypic maturation of mouse BMDCs was analyzed by FACS after a
48 h culture in presence of PBP2 or LPS (from E. coli 0111:B4) alone or in combination with PMB. PMB did not affect PBP2-induced phenotypic
maturation whereas it completely abolished LPS- induced expression of CD40, class II molecules and CD86. Numbers in the graphics represent the
percentage of double-positive cells. n=4. D: Human monocyte-derived DCs were treated for 48 h as for C. The expression of the indicated molecules
was studied by FACS (red histogram plots). Isotype control staining is depicted in each graphic as grey histogram plots. Cell debris were excluded
from the analysis by gating on live cells in the FSC/SSC plot. Representative results from 1 out of 4 donors are depicted. E: PBP2 was left untreated or
treated for 1 h at 37uC with trypsin. The enzyme was then blocked with foetal calf serum and preparations were used to treat DCs for 48 hs. One
experiment representative of three is shown.
doi:10.1371/journal.pone.0023995.g001
Figure 2. PBP2 increases the immunogenic capacities of DCs. A: IL-12p70 and TNF-a levels were quantified in the culture supernatant of DCs
cultured in the presence of the indicated compounds for 48 hs. A mean 6 SD of four experiments is shown. B: Left panel: DDAO-SE-labelled T cells
from BALB/c mice were cultured at different ratios for 72 hs with C57/BL6 BMDC previously treated with the indicated compounds. The mean 6 SD
of divided cells as assessed by DDAO-SE dilution is depicted for two DC/T ratios. n=2. Right panel: Allogeneic untreated and PBP2-treated human
monocyte-derived DCs were c-irradiated and co-cultured for five days with T cells at different DC/T ratios. Proliferation of responder T cells was
studied through analysis of
3H-thymidine uptake. DCs were washed upon PBP2 treatment minimizing the possibility of a direct effect of PBP2 on T
cells. *: p,0.05; **: p,0.01; *: p,0.001. C: Diabetes incidence after transfer of untreated (iDC), LPS or PBP2-treated HA-loaded DCs.
doi:10.1371/journal.pone.0023995.g002
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capsular polysaccharide X (20 mg) or both. Mice were sacrificed 10
days later and immune response, IgG production, was determined
in blood against both PBP2 and purified capsular polysaccharide
of serogroup X by ELISA. As shown in Figure 3, the IgG
response against polysaccharide was enhanced when both antigens
were co-injected in mice while the immune response was mainly
IgM when the polysaccharide was used alone to immunize mice.
Indeed higher IgG/IgM ratio was observed when both antigens
were co-injected compared to the polysaccharide alone. Menin-
gococcal capsular polysaccharide are thymus independent anti-
gens [16]. The response to the protein PBP2 was mainly IgG
(Figure 3). These results show that PBP2 can enhance polyclonal
immune response against meningococcal antigens in vivo. Interest-
ingly, mature DCs were increased in the spleens from immunized
mice with PBP2 and both PBP2 and polysaccharide X compared
to non immunized or mice immunized with polysaccharide X
alone (Figure 4). Indeed, our results suggest that PBP2 induces
DC maturation in vivo promoting immune responses against
meningococcal capsule.
PBP2 induces NF-kB nuclear translocation
We next aimed to characterize the signalling pathway used by
PBP2 to induce DC maturation. We therefore studied whether
PBP2 could induce NF-kB activation. In fact, NF-kB activation is
a critical event in DC maturation, particularly, in inducing pro-
inflammatory cytokines production [17,18]. To study this issue, we
performed confocal microscopy studies analyzing untreated and
PBP2-treated DCs which were stained with an anti-p65 NF-kB
antibody. We therefore analyzed the subcellular localization
(nuclear or cytoplasmic) of p65. Our results clearly showed that
PBP2 induced nuclear translocation of p65 NF-kB( Figure 5A). A
quantification of three different experiments showed that
70.765.1% of PBP2-treated DCs showed nuclear localization of
p65 NF-kB, whereas only 1262.6% of untreated DCs displayed
that staining pattern (Figure 5B). We therefore concluded that
PBP2 induces NF- kB nuclear translocation in DCs.
PBP2-induced DC maturation through TLR4
NF-kB induction is a common pathway downstream TLRs. We
therefore explored the involvement of TLR in mediating the
effects of PBP2. Since PBP2 is a bacterial product, TLR2, TLR3
and TLR4 were initially selected because of their involvement in
recognition of microbial cell wall components [19,20,21]. We
therefore studied MHC class II and co-stimulatory molecules
expression upon PBP2 treatment of WT and TLR-deficient DCs.
No phenotypic differences were found between WT and TLR2
2/2
and TLR3
2/2 DCs (Figure S3) suggesting that these two TLRs
are not involved in PBP2-induced maturation of DCs. In clear
contrast, PBP2 as well as LPS were not able to induce maturation of
TLR4
2/2 DCs. It is worth noting that TLR4
2/2 DCs could be
matured when treated with heat-killed Listeria monocytogenes
(HKLM, TLR2 ligand), showing that TLR4
2/2 DCs were alive
and able to respond to TLR stimulus (Figure 6A). These results
were concomitant with marked decrease of PBP2-induced
IL-12p70 and TNF-a production from TLR4
2/2 derived DCs
compared to WT DCs. (Figure 6B). Taken together, these results
show that TLR4 is needed for PBP2-induced maturation of DCs.
We then studied whether PBP2 could be directly recognized by
TLR4. To asses this, we first performed co-immunoprecipitation
experiments targeting human TLR4 and PBP2. For these
experiments we used Hec-1-B cells, which naturally express
TLR4 (data not shown). Hec-1-B epithelial cells were treated with
10 mg of purified His6-tagged PBP2. Remarkably, we observed
that PBP2 was co-immunoprecipitated with TLR4 when pull-
down was performed with an anti-His tag antibody (Figure 6C,
upperpanel)as wellas with an anti-TLR4antibody (Figure6C,
lower panel). Importantly, through a cellular ELISA assay, we
also showed that binding of PBP2 to TLR4-expressing cells was
inhibited when adding a blocking anti-TLR4 antibody to the
culture (Figure 6D). Interestingly, neither the meningococcal
regulatory protein CrgA and PBP1 nor PBP2 from Helicobacter
pylori could interact with TLR4, although are able to induce
maturation of DC similarly between WT and TLR42/2 mice
(Figure S4 and data not shown). Altogether, our data strongly
suggest that meningococcal PBP2 induces DC maturation by
directly binding TLR4. Other PBPs may induce DC maturation in
TLR4-independent manner.
Discussion
Host bacteria interaction and output of this interaction is largely
dependent on bacterial sensing by host cells [22]. Several bacterial
components are now recognized as PAMPs along with their
corresponding PRRs [22]. Major surface bacterial components
such as lipopolysaccharide and peptidoglycan may be of most
importance in host-bacteria interaction owing to their abundance
and bioavailability. Other bacterial components may also act as
PAMPs. DCs are the most potent antigen presenting cells that
initiate and amplify immune responses [23]. Maturation of DCs by
PAMPs enables DCs to convey pathogen-associated signals to the
adaptive immune system [23]. In this report, we showed that the
meningococcal PBP2 can trigger DC maturation through TLR4.
Figure 3. ELISA based screening of IgM and IgG and immune
response against purified polysaccharide X and PBP2. ELISA
plates were coated with each purified antigen polysaccharide X (A) or
PBP2 (B). The tested sera were from unimmunized mice or mice that
were immunized with purified polysaccharide X, purified PBP2 or both.
Secondary antibodies against the heavy chain of the IgM (Mu chain)
and IgG (gamma chain) were used to detect IgM (black boxes) and IgG
(white boxes) responses respectively. Data were from three indepen-
dent experiments with 4 mice in each group. IgG/IgM ratio (hatched
boxes) are also shown (right side axis). Significant difference in IgG/IgM
ratio is indicated (student t test).
doi:10.1371/journal.pone.0023995.g003
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e23995Figure 4. Flow cytometry analysis of dendritic cells extracted from spleens obtained from BALB/c mice immunized with PBP2 or
with PBP2+polysaccharide X. The gating strategy used is showed in the upper panel. Stainings were then analyzed in the CD11c
+ fraction. MHC
class II and the co-stimulatory molecule CD86 were analyzed in splenic CD11c
hi DCs. The presence of mature DCs under the indicated conditions of
immunization was tested 10 days after immunization. CD86 and MHC class II expression was analyzed by FACS. Low levels, if any, of mature DCs was
detected in unvaccinated mice and those vaccinated with the polysaccharide alone.
doi:10.1371/journal.pone.0023995.g004
Figure 5. PBP2 induces NF-kB nuclear translocation. Mouse BMDCs were treated with 10 mg/ml of PBP2 or left untreated and 30 minutes later
cells were harvested. Subcellular localization of the NF-kB p65 subunit was analyzed using a specific antibody. A: representative images depicting
anti- NF-kB p65 and nuclear staining. B: Quantification of cells showing NF-kB nuclear localization is depicted in the graph. n=3.
doi:10.1371/journal.pone.0023995.g005
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e23995PBP2 is a major enzyme involved in the biosynthesis of
meningococcal peptidoglycan, most likely by acting as a
transpeptidase [1,24]. Its alteration can modify the structure of
peptidoglycan and impact hence on Nod-dependant signalling. It
is therefore of interest that PBP2 itself can also directly signal
through TLR4. Meningococcal components can hence modulate
signalling to host cells [25] and the host’s genetic factors can also
determine the clinical outcome of meningococcal infection [26].
Interestingly, it has been shown that individuals with rare
mutations in TLR4 increase the risk of systemic meningococcal
disease [27]. In addition to meningococcal lipooligosaccharide
(LOS), PBP2 may also be a relevant and direct player in host-
pathogen interactions through TLR4 that influence the clinical
outcome of meningococcal infection. Although the canonical
TLR4 activator is a liposacharidic structure such as LPS, it is
interesting to note that several proteins have been shown to
activate this receptor. Indeed, mammalian endogenous proteins
such as Tenascin-C [28] and HMGB1 [29] have been described as
TLR4 ligands among others. Moreover, F-protein from respira-
tory syncytial virus (RSV) [30] and FimH adhesion from type 1
fimbriae [31,32] have been reported to induce DC maturation
through TLR4. We directly demonstrate through two different
approaches that PBP2 binds human TLR4. This observation
opens the exciting perspective of analyzing how this interaction
takes place at the molecular level. We observed that neither
meningococcal PBP1 nor PBP2 from H. pylori could interact with
TLR4. Moreover, mutant PBP2 harbouring mutations in the
penicillin binding domain, was as effective as WT PBP2 in
inducing DC maturation (unpublished observations). We can
therefore conclude that the penicillin-binding domain is most
likely not involved in TLR4/meningococcal PBP2 interaction.
Our data using several experiment approaches strongly suggest
direct interaction between TLR4 and PBP2 that is responsible for
the maturation of DC. However, we cannot completely exclude a
possible unidentified contaminant in our PBP2 preparation that
may be responsible for this effect. This indirect mechanism has
been recently suggested to explain the ability to induce cytokine of
two intracellular molecular chaperones: the heat shock proteins
and the HMGB1 [33].
However, further work is needed to characterize TLR4/PBP2
interaction. For instance, clinically-relevant TLR4 mutations
could be analyzed from this perspective. We have previously
reported that vaccination with purified recombinant PBP2 was
protective against experimental meningococcemia in mice [34].
This protection may be, at least in part, attributed to induction of
DC maturation and enhanced T cell proliferation. Further works
are needed to explore this possibility. It is noteworthy that PBP2
has a serine-protease domain that may be involved in DC
maturation. Interestingly, vaccination with an internal fragment of
PBP2a of Staphylococcus aureus (comprising the serine-protease
domain as antigen) was also reported to induce a protective
response against methicillin resistant Staphylococcus aureus [35]. PBPs
are conserved proteins expressed only on pathogens and not in
mammalian cells. Further studies are needed to determine whether
other PBPs from meningococci and from other pathogens can
work as PAMPs. Meningococcal polysaccharide vaccines have
been developed to induce specific antibodies for protection of
high-risk populations from meningococcal infections. However,
the purified polysaccharide vaccines are less immunogenic,
especially in young children -the population in which meningo-
coccal diseases are prevalent-, and is characterized primarily by
IgM antibodies, rare IgG and no immunological memory.
Conjugation of the polysaccharide to carrier proteins such as
tetanus toxoid and diphtheria toxin or its genetic mutant CRM197
improved the immunological response in terms of isotype antibody
switching from IgM to IgG, which is more protective against
meningococcal infection and the anamnestic response
[36,37,38,39]. Nevertheless, the use of these proteins as universal
carriers may induce a reduction of the response against several
vaccines that are administered during infancy and share common
protein epitopes by inducing epitopic overload and hapten-specific
carrier-induced suppression [40,41,42]. The characterization of
new carrier proteins seems to be a compulsory step for the
achievement of a proper immune response against meningococcal
polysaccharide needed for childhood vaccination. Classical
adjuvants often contain ligands that stimulate TLR signaling of
innate immune cells [43] and vaccines that incorporate ligands for
TLR stimulation were shown to boost vaccine responses [44,45].
PBP2 as a TLR4 ligand may therefore act as an adjuvant through
maturation of DCs as also suggested by experiments of co-
immunization of PBP2 and capsular polysaccharide with higher
IgG immune response and higher IgG/IgM ratio suggesting that
PBP2 may have adjuvant properties affecting immunoglobulin
class switch for a thymus independent antigen from IgM to IgG
[46]. Further studies are needed to determine whether PBP2 is a
safer molecule than LPS to be used as an immunological adjuvant
in vivo [47]. In Summary, our data suggest that PBP2 plays a key
role in the interface between innate and adaptive immunity and
may represent an interesting candidate to develop anti-meningo-
coccal vaccines or to enhance immune response of other vaccine
candidate throughout induction of DC maturation and T-cell
proliferation and thus contribute to eliminate the epitopic overload
and hapten-specific carrier-induced suppression that could take
place when the same protein carrier is used in subsequent
vaccination routines.
Supporting Information
Figure S1 PBP2 induces DC maturation in a dose-
dependent manner. Mouse BMDC were stimulated for 48 h
with the indicated doses of PBP2. The mean fluorescence intensity
(MFI) was determined for each maturation marker depicted in the
Y axis of the graphics. LOGEC50 6 SD calculated from two
independent experiments is shown in each graphic (mg/ml).
(PPT)
Figure S2 Highly purified PBP2 induces DC matura-
tion. PBP2 issued from Nickel-affinity column has been fur-
ther purified using anion-exchange chromatography. A: FPLC
profile of the eluted fractions B: SDS-PAGE analysis of
PBP2 preparations. Left panel, Nickel affinity purified PBP2
Figure 6. PBP2 fails in inducing maturation in TLR42/2 DCs. WT and TLR4
2/2 DCs cultured for 48 h in the presence of PBP2 (5 mg/ml), LPS
(50 ng/ml) or Heat-killed L. monocytogenes (HKLM, 10
8 CFU/ml). A: Analysis of phenotypic markers. One representative experiment of two is shown.
B: IL-12p70 and TNF-a production in the culture supernatant. The mean 6 SD of two independent experiments is shown. C: Hec-1-B epithelial cells
(expressing TLR4) were treated with 10 mg His6-tagged PBP2. Anti-TLR4 (upper panel) or anti-His6 (lower panel) were used to pull down the target
protein. Immunoblot was then performed with anti-His6 (upper panel) or anti-TLR4 (lower panel). D: A cellular ELISA assay was performed to show
that PBP2 binds to TLR4 on Hec-1-B cells. Cells were treated for 1 h at 37uC with increasing amounts of purified His-tagged PBP2 in presence of anti-
TLR4 blocking antibodies (clone HTA125 eBioscience, Hatfield, UK) or an irrelevant normal mouse IgG (10 mg). Bound PBP2 was detected using anti-
His-tag polyclonal antibody followed by HRPO-conjugated goat anti-rabbit antibody. In C and D one experiment representative of three is depicted.
doi:10.1371/journal.pone.0023995.g006
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e23995(PBP2NI column, lane 1) was analyzed along with anion-exchange
chromatography eluted fractions F1–F3 (lanes 2–4). The whole
cell lysate (WCL) is shown in the left. The gel was submitted to
coomassie staining. Only fraction F2 contains PBP2. Right panel,
decreasing amounts of PBP2 from fraction F2 were further
examined for contaminating bands and LPS by silver staining
along with decreasing amounts of LPS. Whole cell lysates from
bacteria transformed with pET28b empty vector or PBP2-
expressing vector pAA2 were shown as controls. Molecular weight
markers are indicated. C: DCs were left untreated, or alternatively
treated with PBP2NI column, the eluted fractions F1–F3 or LPS in
the presence or not of PMB. DCs were then phenotypically studied
by FACS. D: PBP2 purified from nickel columns were pre-
incubated with anti-PBP2 or irrelevant antibodies and then used to
treat DCs which were phenotipically studied by FACS. Numbers
represent percentages of each quadrant in FACS figures.
(PPT)
Figure S3 TLR2 and TLR3 are not needed by PBP2 to
induce DC maturation. Phenotypical analysis of WT,
TLR22/2 and TLR32/2 DCs was performed upon PBP2
treatment and compared to untreated cells. Numbers in the dot
plots represent the percentage of events in each quadrant.
(PPT)
Figure S4 Meningococcal CrgA and PBP1 as well as
PBP2 from Helicobacter pylori induce DC maturation in
a TLR4-independent manner. A: Study of DC phenotypic
maturation upon treatment with the indicated proteins in WT and
TLR42/2 DCs. The numbers represent the percentage of cells in
each quadrant. B: Immunoprecipitation studies showing that
meningococcal PBP2 but not the other proteins studied co
immunoprecipitates with TLR4.
(PPT)
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